Cargando…

Circulating microRNA Profiles for Premature Cardiovascular Death in Patients with Kidney Failure with Replacement Therapy

Introduction: Patients with kidney failure with replacement therapy (KFRT) suffer from a disproportionately high cardiovascular disease burden. Circulating small non-coding RNAs (c-sncRNAs) have emerged as novel epigenetic regulators and are suggested as novel biomarkers and therapeutic targets for...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuscu, Canan, Mallisetty, Yamini, Naik, Surabhi, Han, Zhongji, Berta, Caleb J., Kuscu, Cem, Kovesdy, Csaba P., Sumida, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419472/
https://www.ncbi.nlm.nih.gov/pubmed/37568412
http://dx.doi.org/10.3390/jcm12155010
_version_ 1785088526754250752
author Kuscu, Canan
Mallisetty, Yamini
Naik, Surabhi
Han, Zhongji
Berta, Caleb J.
Kuscu, Cem
Kovesdy, Csaba P.
Sumida, Keiichi
author_facet Kuscu, Canan
Mallisetty, Yamini
Naik, Surabhi
Han, Zhongji
Berta, Caleb J.
Kuscu, Cem
Kovesdy, Csaba P.
Sumida, Keiichi
author_sort Kuscu, Canan
collection PubMed
description Introduction: Patients with kidney failure with replacement therapy (KFRT) suffer from a disproportionately high cardiovascular disease burden. Circulating small non-coding RNAs (c-sncRNAs) have emerged as novel epigenetic regulators and are suggested as novel biomarkers and therapeutic targets for cardiovascular disease; however, little is known about the associations of c-sncRNAs with premature cardiovascular death in KFRT. Methods: In a pilot case-control study of 50 hemodialysis patients who died of cardiovascular events as cases, and 50 matched hemodialysis controls who remained alive during a median follow-up of 2.0 years, we performed c-sncRNAs profiles using next-generation sequencing to identify differentially expressed circulating microRNAs (c-miRNAs) between the plasma of cases and that of controls. mRNA target prediction and pathway enrichment analysis were performed to examine the functional relevance of differentially expressed c-miRNAs to cardiovascular pathophysiology. The association of differentially expressed c-miRNAs with cardiovascular mortality was examined using multivariable conditional logistic regression. Results: The patient characteristics were similar between cases and controls, with a mean age of 63 years, 48% male, and 54% African American in both groups. We detected a total of 613 miRNAs in the plasma, among which five miRNAs (i.e., miR-129-1-5p, miR-500b-3p, miR-125b-1-3p, miR-3648-2-5p, and miR-3150b-3p) were identified to be differentially expressed between cases and controls with cut-offs of p < 0.05 and log2 fold-change (log2FC) > 1. When using more stringent cut-offs of p-adjusted < 0.05 and log2FC > 1, only miR-129-1-5p remained significantly differentially expressed, with higher levels of miR-129-1-5p in the cases than in the controls. The pathway enrichment analysis using predicted miR-129-1-5p mRNA targets demonstrated enrichment in adrenergic signaling in cardiomyocytes, arrhythmogenic right ventricular cardiomyopathy, and oxytocin signaling pathways. In parallel, the circulating miR-129-1-5p levels were significantly associated with the risk of cardiovascular death (adjusted OR [95% CI], 1.68 [1.01–2.81] for one increase in log-transformed miR-129-1-5p counts), independent of potential confounders. Conclusions: Circulating miR-129-1-5p may serve as a novel biomarker for premature cardiovascular death in KFRT.
format Online
Article
Text
id pubmed-10419472
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104194722023-08-12 Circulating microRNA Profiles for Premature Cardiovascular Death in Patients with Kidney Failure with Replacement Therapy Kuscu, Canan Mallisetty, Yamini Naik, Surabhi Han, Zhongji Berta, Caleb J. Kuscu, Cem Kovesdy, Csaba P. Sumida, Keiichi J Clin Med Article Introduction: Patients with kidney failure with replacement therapy (KFRT) suffer from a disproportionately high cardiovascular disease burden. Circulating small non-coding RNAs (c-sncRNAs) have emerged as novel epigenetic regulators and are suggested as novel biomarkers and therapeutic targets for cardiovascular disease; however, little is known about the associations of c-sncRNAs with premature cardiovascular death in KFRT. Methods: In a pilot case-control study of 50 hemodialysis patients who died of cardiovascular events as cases, and 50 matched hemodialysis controls who remained alive during a median follow-up of 2.0 years, we performed c-sncRNAs profiles using next-generation sequencing to identify differentially expressed circulating microRNAs (c-miRNAs) between the plasma of cases and that of controls. mRNA target prediction and pathway enrichment analysis were performed to examine the functional relevance of differentially expressed c-miRNAs to cardiovascular pathophysiology. The association of differentially expressed c-miRNAs with cardiovascular mortality was examined using multivariable conditional logistic regression. Results: The patient characteristics were similar between cases and controls, with a mean age of 63 years, 48% male, and 54% African American in both groups. We detected a total of 613 miRNAs in the plasma, among which five miRNAs (i.e., miR-129-1-5p, miR-500b-3p, miR-125b-1-3p, miR-3648-2-5p, and miR-3150b-3p) were identified to be differentially expressed between cases and controls with cut-offs of p < 0.05 and log2 fold-change (log2FC) > 1. When using more stringent cut-offs of p-adjusted < 0.05 and log2FC > 1, only miR-129-1-5p remained significantly differentially expressed, with higher levels of miR-129-1-5p in the cases than in the controls. The pathway enrichment analysis using predicted miR-129-1-5p mRNA targets demonstrated enrichment in adrenergic signaling in cardiomyocytes, arrhythmogenic right ventricular cardiomyopathy, and oxytocin signaling pathways. In parallel, the circulating miR-129-1-5p levels were significantly associated with the risk of cardiovascular death (adjusted OR [95% CI], 1.68 [1.01–2.81] for one increase in log-transformed miR-129-1-5p counts), independent of potential confounders. Conclusions: Circulating miR-129-1-5p may serve as a novel biomarker for premature cardiovascular death in KFRT. MDPI 2023-07-30 /pmc/articles/PMC10419472/ /pubmed/37568412 http://dx.doi.org/10.3390/jcm12155010 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kuscu, Canan
Mallisetty, Yamini
Naik, Surabhi
Han, Zhongji
Berta, Caleb J.
Kuscu, Cem
Kovesdy, Csaba P.
Sumida, Keiichi
Circulating microRNA Profiles for Premature Cardiovascular Death in Patients with Kidney Failure with Replacement Therapy
title Circulating microRNA Profiles for Premature Cardiovascular Death in Patients with Kidney Failure with Replacement Therapy
title_full Circulating microRNA Profiles for Premature Cardiovascular Death in Patients with Kidney Failure with Replacement Therapy
title_fullStr Circulating microRNA Profiles for Premature Cardiovascular Death in Patients with Kidney Failure with Replacement Therapy
title_full_unstemmed Circulating microRNA Profiles for Premature Cardiovascular Death in Patients with Kidney Failure with Replacement Therapy
title_short Circulating microRNA Profiles for Premature Cardiovascular Death in Patients with Kidney Failure with Replacement Therapy
title_sort circulating microrna profiles for premature cardiovascular death in patients with kidney failure with replacement therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419472/
https://www.ncbi.nlm.nih.gov/pubmed/37568412
http://dx.doi.org/10.3390/jcm12155010
work_keys_str_mv AT kuscucanan circulatingmicrornaprofilesforprematurecardiovasculardeathinpatientswithkidneyfailurewithreplacementtherapy
AT mallisettyyamini circulatingmicrornaprofilesforprematurecardiovasculardeathinpatientswithkidneyfailurewithreplacementtherapy
AT naiksurabhi circulatingmicrornaprofilesforprematurecardiovasculardeathinpatientswithkidneyfailurewithreplacementtherapy
AT hanzhongji circulatingmicrornaprofilesforprematurecardiovasculardeathinpatientswithkidneyfailurewithreplacementtherapy
AT bertacalebj circulatingmicrornaprofilesforprematurecardiovasculardeathinpatientswithkidneyfailurewithreplacementtherapy
AT kuscucem circulatingmicrornaprofilesforprematurecardiovasculardeathinpatientswithkidneyfailurewithreplacementtherapy
AT kovesdycsabap circulatingmicrornaprofilesforprematurecardiovasculardeathinpatientswithkidneyfailurewithreplacementtherapy
AT sumidakeiichi circulatingmicrornaprofilesforprematurecardiovasculardeathinpatientswithkidneyfailurewithreplacementtherapy